Drug class
PSMA-targeting ligand; diagnostic radiopharmaceutical component for gallium-68 PET imaging
Mechanism of action
The Glu-urea-Lys(Ahx) peptide ligand binds prostate-specific membrane antigen (PSMA) on prostate epithelial cells and commonly overexpressed on prostate cancer cells. When conjugated to the HBED-CC chelator and radiolabelled with gallium-68, the resulting radioconjugate enables PET visualisation of PSMA-expressing lesions.
General use cases
- Used as the active ligand in gallium Ga-68 gozetotide (PSMA-11) injection for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated PSA.
- The unlabelled ligand is not itself a radioactive imaging agent; diagnostic imaging requires the labelled gallium-68 product.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
